Condition: Congenital Adrenal Hyperplasia · Classic Congenital Adrenal Hyperplasia · Sponsor: Crinetics Pharmaceuticals Inc.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
This description comes directly from the study's public registry record.
Crinetics Clinical Trials · 833-827-9741 · clinicaltrials@crinetics.com
Always discuss trial participation with your own doctor first.
| Crinetics Study Site, Minneapolis, Minnesota 55454 | Minneapolis, Minnesota, United States | Active Not Recruiting |
| Crinetics Study Site | Morehead City, North Carolina, United States | Active Not Recruiting |
| Crinetics Study Site | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
| Crinetics Study Site | Córdoba, Córdoba Province, Argentina | Recruiting |
| Crinetics Study Site | Curitiba, Paraná, Brazil | Recruiting |
| Crinetics Study Site | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| Crinetics Study Site | Botucatu, São Paulo, Brazil | Recruiting |
| Crinetics Study Site | Rio de Janeiro, Brazil | Recruiting |
| Crinetics Study Site | São Paulo, Brazil | Recruiting |
| Crinetics Study Site | Munich, Bavaria, Germany | Recruiting |
| Crinetics Study Site | Roma, Italy | Recruiting |
| Crinetics Study Site | Birmingham, United Kingdom | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06712823